Munich/Martinsried, Germany, December 2, 2013 / B3C newswire / -ProJect Pharmaceutics announces that it has signed a development agreement with ImevaX, a spin-off project from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institute for Medicinal Microbiology, Immunology and Hygiene, aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multicomponent vaccine, making the formulation development particularly challenging.
The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimized protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analyzing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing.
Promising formulation candidates have successfully been evaluated and are continuously optimized within the development program since its launch in mid 2013.
Financial terms of the current agreement are not disclosed.
About ProJect Pharmaceutics
ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and cytotoxic molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying innovative concepts of pharmaceutical development.
ProJect Pharmaceutics makes sure that investigational products as well as new presentations of registered drugs are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.
About ImevaX
As part of the GO-Bio start up program of the German Ministry of Research and Education (BMBF), the TUM-based Spin-off project ImevaX from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institue for Medicinal Microbiology, Immunology and Hygiene, develops highly specific vaccines against pathogens that cause chronic infectious diseases. Its technology identifies immune modulatory bacterial factors that are then used to develop effective vaccines against infections of global relevance. ImevaX is planned to be founded as a biotech company in 2014.
Contacts
ProJect Pharmaceutics GmbH
Fraunhoferstraße 22
D-82152 Martinsried
+49 (0) 89 452289700
Dr. Andreas Schütz: This email address is being protected from spambots. You need JavaScript enabled to view it.
Klaus Hellerbrand: This email address is being protected from spambots. You need JavaScript enabled to view it.
ImevaX
Medizinische Mikrobiologie, Immunologie und Hygiene
Trogerstraße 30
D-81675 München
+49 (0) 89 4140 2477
Prof. Dr. Markus Gerhard: This email address is being protected from spambots. You need JavaScript enabled to view it.